Roche's Tecentriq is the first I-O drug to claim a post-surgery win in lung cancer. But will doctors use it?

Industry watchers have pegged PD-1/L1 cancer immunotherapies’ next phase of growth on their potential in the pre- and post-surgery settings. And Roche has claimed the first win for such a use in the all-important non-small cell lung cancer arena.